All News
Low-grade Proteinuria in Non Renal Lupus: Should We be Worried?
Dr. Yuz Yusof ( @Yuz6Yusof) discusses Abstract 1463 presented at #ACR22
https://t.co/v5fHfwvapv https://t.co/zf2kJy23r2
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioid use in PsA and SpA
Dr. Eric Dein discusses Abstract 1012 at ACR22 Convergence
https://t.co/Doxbk7qW33 https://t.co/2UX07T2JpS
Links:
Dr. John Cush RheumNow ( View Tweet)
CAR-T Therapies in Antiphospholipid Antibody Syndrome
Dr. Putman and Dr. Konig discuss abstract 1677 at ACR22 Convergence. Abstract 1677: Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
https://t.co/VeAgl3qz8J https://t.co/rN4ZLM5Ft8
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe!
Rheum Manpower Needs - More Programs
https://t.co/xGXVFMkNra https://t.co/hcRGVMFZPE
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study looked at 47 adults w/ dermatomyositis treated with tofacitinib. While clinically similar, those on TOFA were were younger (53vs 61), shorter Rx duration (24 vs 53 mos);there was signif CDASI improvement. #ACR22 https://t.co/PEPmzZPeFr https://t.co/sS7IiYW9PR
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/2QL2mz7Zhk https://t.co/YQ7jG1WnAG
Links:
Dr. John Cush RheumNow ( View Tweet)
View our interactive case study from the #SLEEducatorsNetwork to discover how you can apply the concept of disease modification to your patients with lupus. #Sponsored by GSK USMA
https://t.co/not76wZPnI https://t.co/Reot2JbWpF
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/11dneH04bv https://t.co/pp0ELe5mqV
Links:
Dr. John Cush RheumNow ( View Tweet)
NRMP Results for rheumatology 2022 :
- Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied)
- Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied)
WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/sqcIXxWrxx https://t.co/9xeUQeAuDD
Links:
Dr. John Cush RheumNow ( View Tweet)
Remibrutinib in Sjogren's Syndrome
Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
https://t.co/ZcKU7MgXlm https://t.co/P9JBlxcdcx
Links:
Dr. John Cush RheumNow ( View Tweet)
Steroid injections worsen knee arthritis
Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.
https://t.co/pAeU3IzZfx https://t.co/rgJeHM5t62
Links:
Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance.
https… https://t.co/r0AlTD45gG
Dr. John Cush RheumNow ( View Tweet)
ACR22: Polymyalgia Rheumatica in the Spotlight
One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run.
https://t.co/4BpvYlKijY https://t.co/fTYYdmcE9X
Links:
Dr. John Cush RheumNow ( View Tweet)
Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/z3RTFt1hPb https://t.co/7rGn41qeu9
Links:
Dr. John Cush RheumNow ( View Tweet)
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22.
https://t.co/s8FQ2l7k6Z https://t.co/zICWqhTfGL
Links:
Dr. John Cush RheumNow ( View Tweet)
Proceedings of the Royal Society of Medicine and Fibromyalgia Action UK Webinar: Fibromyalgia in the 21st century: Redefining care. https://t.co/s02Ue47m6o https://t.co/FZYI7E8D3f
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/CVDbXtqOBw https://t.co/R4ed2FNxdh
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/Qyp2odOfpj https://t.co/Q1qdv0CQ5P
Links:
Dr. John Cush RheumNow ( View Tweet)
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
https://t.co/6pqRZO2VNA https://t.co/iJfhyRs8nw
Links:
Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Links:
Dr. John Cush RheumNow ( View Tweet)